Iovance Biotherapeutics: Several Positives, But Competition Still Threatens (NASDAQ:IOVA)

In August, I noted Iovance Biotherapeutics ( IOVA ) had made a step in the right direction with its Q2'25 earnings, but given the previous missteps in the launch of Amtagvi, I wasn't willing to rate the name a buy,Scientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/we have a beneficial l ...